Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994508 | 0.91 | NPC1 (0.39) | GCKALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL3012154 | 0.90 | GRM5 (0.43) | GCKALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL2210683 | 0.88 | GCK (0.55) | GCKALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL3003101 | 0.86 | GRM5 (0.43) | GCKALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL3010505 | 0.82 | POLB (0.42) | GCKALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL2997075 | 0.81 | HPGDS (0.45) | GCKALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL3008721 | 0.80 | HPGDS (0.45) | GCKALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL3007341 | 0.80 | GCK (0.40) | GCKNPC1RAB9AKMT2AMAPT | |
| SCHEMBL2211361 | 0.78 | GCK (0.59) | GCK | |
| SCHEMBL2211373 | 0.78 | GCK (0.53) | GCKALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190980-A1 | PYRAZINAMIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-07-29 | — | — | US | claimed |
| EP-2157090-A1 | PYRAZINAMIDE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-02-24 | — | — | EP | claimed |
| US-20100190980-A1 | PYRAZINAMIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2157090-A1 | PYRAZINAMIDE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190980-A1 | PYRAZINAMIDE COMPOUND | KAT8, GK, KCNJ8 | GCK 25/4885ALDH1A1 2753/4885NPC1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.